Ex­elix­is/Dai­ichi Sankyo ask Japan­ese reg­u­la­tors for green light on hy­per­ten­sion drug; Bris­tol-My­ers Squibb li­cens­es GPCR tech from Do­main Ther­a­peu­tics

→ San Fran­cis­co’s Ex­elix­is $EX­EL — and its part­ner Dai­ichi Sankyo — has asked Japan­ese reg­u­la­tors for the OK to sell their in­ves­ti­ga­tion­al hy­per­ten­sion drug called …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER